Immune-mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non-small cell lung cancer patient: A case report

Thorac Cancer. 2021 Oct;12(20):2811-2814. doi: 10.1111/1759-7714.14106. Epub 2021 Aug 17.


We describe a case of a 60-year-old man with a prolonged thrombocytopenia during a durvalumab maintenance therapy after chemoradiotherapy for locally advanced non-small cell lung carcinoma. Bone marrow specimen was normoplastic with the marked megakaryocyte depletion, which was assumed to be an acquired amegakaryocytic thrombocytopenic purpura. Although hematological disorders as immune-related adverse events (irAE) are rare, we should pay more attention to hematological disorders with durvalumab especially after concurrent chemoradiotherapy.

Keywords: amegakaryocytic thrombocytopenic purpura; concurrent chemoradiotherapy; immune checkpoint inhibitor; immune-mediated thrombocytopenia.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / radiotherapy
  • Chemoradiotherapy / methods
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / radiotherapy
  • Male
  • Middle Aged
  • Thrombocytopenia / chemically induced*
  • Thrombocytopenia / immunology


  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • durvalumab